Central Nervous System News and Research

RSS

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).

8 Dec 2009

Multi-institutional team explores regenerative techniques for injured spinal cords

For more than 400 years, scientists have studied the amazing regenerative power of salamanders, trying to understand how these creatures routinely repair injuries that would usually leave humans and other mammals paralyzed - or worse.

8 Dec 2009

Study shows positive association between adolescent fitness and cognitive performance

In the first study to demonstrate a clear positive association between adolescent fitness and adult cognitive performance, Nancy Pedersen of the University of Southern California and colleagues in Sweden find that better cardiovascular health among teenage boys correlates to higher scores on a range of intelligence tests - and more education and income later in life.

8 Dec 2009

$225,000 funding for promising epilepsy research

The Epilepsy Research Foundation (ERF), a unique joint venture of non-profit epilepsy organizations, and the Milken Family Foundation, a private philanthropic foundation, today announced two new grants recognizing promising epilepsy research in clinical development, totaling $225,000 in funding. The grant awards were announced by the Epilepsy Therapy Project and the Epilepsy Foundation, as well as the Milken Family Foundation, during the 7th Judith Hoyer Lecture in Epilepsy at the annual meeting of the American Epilepsy Society in Boston, MA.

7 Dec 2009

FDA approves two New Drug Applications

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved its first two New Drug Applications (NDAs) based on its proprietary OralXR+(TM) platform technology including the first-ever 24 hour liquid sustained release product.

7 Dec 2009

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

6 Dec 2009

Late recurrence of Ewing sarcomas and astrocytomas: A risk for some pediatric cancers

Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the National Cancer Institute.

5 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

StemCells welcomes NIH's approval of the first 13 human embryonic stem cell lines for research

StemCells, Inc. announced today that it welcomes the approval yesterday by the National Institutes of Health (NIH) of the first 13 human embryonic stem cell (hESC) lines for use in NIH-funded research under the NIH Guidelines for Human Stem Cell Research adopted in July 2009.

4 Dec 2009

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company’s gene transfer approach to the treatment of advanced Parkinson’s disease.

4 Dec 2009

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

Rules-Based Medicine, Inc. (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia.

3 Dec 2009

Study shows CIMT may be effective for treating hemiplegic cerebral palsy, but calls for more research

Constraint-induced movement therapy (CIMT) is a potentially effective form of intervention for children with hemiplegic cerebral palsy, but more research is needed, according to a new systematic review published in the November issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association (APTA).

3 Dec 2009

AANS and CNS join other surgical organizations to oppose 'Patient Protection and Affordable Care Act'

The American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) have joined 17 other surgical organizations in opposing the “Patient Protection and Affordable Care Act” introduced by Senate Majority Leader Harry Reid.

2 Dec 2009

Galenea and Otsuka Pharmaceutical extend their research and development collaboration

Galenea Corp. and Otsuka Pharmaceutical Co., Ltd. announced today the further extension of their research and development collaboration through 2011. This latest extension increases the collaboration term to seven years and brings the total committed funding to approximately $90 million.

2 Dec 2009

Glutamatergic nerve cells regularly generated in the brain

Until only a few years ago, neurogenesis - the process of nerve cell development - was considered to be impossible in the adult brain. The textbooks asserted that dead nerve cells could not be replaced. Then researchers discovered regions in the forebrain in humans in which new nerve cells can be generated throughout life. These so-called GABAergic cells use gamma-aminobutyric acid (GABA), a neurotransmitter of the central nervous system.

1 Dec 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Cannasat Therapeutics reports net loss of $336,154 for the three months ended September 30, 2009

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders, today announced its results for the nine months ended September 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

27 Nov 2009

Multiple Sclerosis Society of Canada to invite research operating grant proposals related to CCSVI and MS

The Multiple Sclerosis Society of Canada announced it will request research operating grants related to chronic cerebrospinal venous insufficiency (CCSVI) and MS.

25 Nov 2009

Medical care in Germany for children with cancer is very good: IQWiG report

Internationally viewed, medical care in Germany for children with cancer is very good as far as survival is concerned. However, other aspects, such as quality of life, pain, and long-term consequences of the disease are still insufficiently investigated in studies. This is the conclusion of the Institute for Quality and Efficiency in Health Care (IQWiG) in its final report published on 16 October 2009.

25 Nov 2009

Central Nervous System News and Research

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Multi-institutional team explores regenerative techniques for injured spinal cords

Study shows positive association between adolescent fitness and cognitive performance

$225,000 funding for promising epilepsy research

FDA approves two New Drug Applications

Stem cell treatment: A new hope for Multiple Sclerosis

Late recurrence of Ewing sarcomas and astrocytomas: A risk for some pediatric cancers

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

StemCells welcomes NIH's approval of the first 13 human embryonic stem cell lines for research

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

Study shows CIMT may be effective for treating hemiplegic cerebral palsy, but calls for more research

AANS and CNS join other surgical organizations to oppose 'Patient Protection and Affordable Care Act'

Galenea and Otsuka Pharmaceutical extend their research and development collaboration

Glutamatergic nerve cells regularly generated in the brain

ALS research collaboration receives philanthropic funding

Cannasat Therapeutics reports net loss of $336,154 for the three months ended September 30, 2009

Multiple Sclerosis Society of Canada to invite research operating grant proposals related to CCSVI and MS

Medical care in Germany for children with cancer is very good: IQWiG report

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News